Navigation Links
Instituto Gulbenkian de Ciencia scientist wins new Portuguese award Simbiontes for cancer research
Date:12/15/2010

The Simbiontes ("Symbionts" in English) Project brought together children, their families, artists and scientists in a first of its kind fundraising project in Portugal. A true symbiosis was established between several groups in society, leading to this award for scientific research.

Miguel Godinho Ferreira, group leader at the Instituto Gulbenkian de Cincia, just outside Lisbon, is the first scientist to win the 10,000 euros Simbiontes Award, for his proposal to investigate the cellular changes that cause cancer in adults. Over 80% of cancers appear in adults over 50, making age one of the main risk factors for this disease. Miguel Godinho Ferreira's research promises crucial insights into understanding the causes of cancer, and, potentially, into developing approaches to fight the disease.

Miguel's research interests lie in understanding why the incidence of cancer increases with age. He believes he has a clue as to what may underlie this phenomenon: "Chromosome ends have on them protective structures, made up of DNA, called telomeres. As we age, telomeres become shorter, thus acting like molecular clocks that convey the age of a cell."

Telomeres undergo lifelong wear and tear because the enzyme that builds them is not active in human cells. Indeed, telomerase - as this enzyme is called - is active only in the embryo, and becomes inactive at birth. Miguel and his team are looking for the signals associated to telomerase in young cells, that are absent in old cells. They hope to harness these molecular signals to stop cancer developing in older cells. Says Miguel, "If we could manipulate telomerase so that old cells could be tricked into believing they are younger than they really are, it might just be possible to stop cancer from developing. In this project we will try to prove this hypothesis, using first a model organism (yeast), then extending our findings into human cells, and, potentially, paving the way for new therapies.

Miguel Godinho Ferreira's project was chosen amongst 26 proposals that were submitted to an international panel of cancer research experts. The award marks the endpoint of the first edition of the Simbiontes project, put in place by the Associao Viver a Cincia, in collaboration with the Portuguese Institute of Oncology in Lisbon and the arts school Ar.Co. The aim of the project is to raise funds for research, through the engagement of several groups in society. A series of art workshops were run with children at the Institute of Oncology, based on the book "A Menina do Mar" by Sophia de Mello Breyner. The children made several paintings and drawings, that were auctioned in 2009. Furthermore, an illustrated children's book, titled "Os Amigos da Menina do Mar", by Raquel Gaspar (a biologist) and ngelo Encarnao (an artist), was published. The funds raised from the auction of the paintings and drawings, the sales of the book and other activities make up the Simbiontes award.

Miguel adds, "It is an honour to receive the Simbiontes award, for it's spirit as the public's contribution to scientific research. The value of the award is a small contribution to the project, since scientific research is very expensive, but it will allow us to be bolder in our research".


'/>"/>

Contact: Ana Godinho
agodinho@igc.gulbenkian.pt
351-214-407-959
Instituto Gulbenkian de Ciencia
Source:Eurekalert  

Related medicine news :

1. Scientists Pinpoint Area of Brain That Fears Losing Money
2. Scientists Discover How HIV Is Transmitted Between Men
3. Prevention Is Key Research Goal for Premature Babies, Scientists Say
4. Mensa GLAAM Conference to Feature Christian Drapeau, Stem Cell Author and Scientist
5. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
6. Scientists find donut-shaped structure of enzyme involved in energy metabolism
7. Neuroscientists reveal new links that regulate brain electrical activity
8. Two UCSF Scientists to Receive Prestigious Dementia Research Honor
9. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
10. Scientists Spot Genetic Fingerprints of Individual Cancers
11. AADR awards the 2010 Distinguished Scientist Award to John Greenspan
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Instituto Gulbenkian de Ciencia scientist wins new Portuguese award Simbiontes for cancer research
(Date:2/10/2016)... Tucson, AZ (PRWEB) , ... February 10, 2016 , ... ... prompted the Aging Life Care Association™ (ALCA) to conduct a survey that takes a ... aging experts released today illustrates the prevalence and causes of TBI among the aging ...
(Date:2/10/2016)... ... 10, 2016 , ... United Benefit Advisors (UBA), the nation’s ... to its growing list of Partner Firms. S.S. Nesbitt is headquartered in ... Huntsville and in between. , Harnessing the experience and insights of the agency’s ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... AxoGen, Inc. ... will report results for the fourth quarter and full year ended December 31, 2015 ... a conference call and webcast for the investment community following the release at 4:30 ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The Association for ... speaker Jan Fox will serve as keynote speaker at the organization’s 2016 Spring ... tools to more effectively communicate with their own organizational staff and leadership. ...
(Date:2/10/2016)... AZ (PRWEB) , ... February 10, 2016 , ... For ... in new book , Pioneering book "Better with Age: The Ultimate Guide to Brain ... neuroplasticity can improve memory. The book’s publication date is March 16, 2016. ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... BASEL, Switzerland and SAN DIEGO ... Houston , Inc., a global leader in viral gene ... gene therapy treatments for congestive heart failure and other ... to develop a scalable manufacturing process and produce cGMP-grade ... clinical trials. --> ...
(Date:2/10/2016)... NEW YORK , Feb. 10, 2016 ... clinical-stage biopharmaceutical company, announced today that it has filed ... Myeloid Leukemia and other cancers. --> ... of treating cancer by administration of Ceplene (histamine dihydrochloride) ... also provides methods of predicting the efficacy of Ceplene ...
(Date:2/10/2016)... , Feb. 10, 2016  Oxis International Inc. ... drug, OXS-1550, was described as a "clinical trial triumph" ... drug went into complete cancer remission. ... of Minnesota Masonic Cancer Center. --> ... of Minnesota Masonic Cancer Center. --> ...
Breaking Medicine Technology: